Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

BACKGROUND: Cognitive impairment is common in multiple sclerosis (MS), with cognitive processing speed being the most frequently affected domain. OBJECTIVE: Examine the effects of daclizumab beta versus intramuscular (IM) interferon (IFN) beta-1a on cognitive processing speed as assessed by Symbol D...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mult Scler
Huvudupphovsmän: Benedict, Ralph HB, Cohan, Stanley, Lynch, Sharon G, Riester, Katherine, Wang, Ping, Castro-Borrero, Wanda, Elkins, Jacob, Sabatella, Guido
Materialtyp: Artigo
Språk:Inglês
Publicerad: SAGE Publications 2017
Ämnen:
Original Research Papers
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5971365/
https://ncbi.nlm.nih.gov/pubmed/28485186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517707345
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk